Trial Profile
Efficacy and Tolerability of Olopatadine and Azelastine in a 2-Week Vasomotor Rhinitis Trial.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Apr 2011
Price :
$35
*
At a glance
- Drugs Azelastine (Primary) ; Olopatadine (Primary)
- Indications Vasomotor rhinitis
- Focus Therapeutic Use
- 05 Apr 2011 Status changed from not stated to completed.
- 04 Mar 2011 New trial record